Table 2.

Cochrane risk of bias summary of included RCTs

Study	Random Sequence Generation	Allocation Concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective outcome reporting	Other sources of bias
Sandfeldt 2001 [10]	Unclear risk	low risk	low risk	low risk	low risk	low risk	low risk
HäggstrÖm 2002 [13]	Unclear risk	Unclear risk	high risk	high risk	low risk	low risk	low risk
Donohue 2002 [8]	Unclear risk	Unclear risk	low risk	Unclear risk	low risk	low risk	low risk
Liu 2003 [5]	Unclear risk	Unclear risk	high risk	high risk	high risk	low risk	low risk
Li 2004 [6]	Unclear risk	Unclear risk	high risk	high risk	high risk	low risk	low risk
Özdal 2005 [4]	Unclear risk	Unclear risk	low risk	Unclear risk	low risk	low risk	low risk
Lund 2005 [19]	low risk	low risk	Unclear risk	Unclear risk	low risk	low risk	low risk
Boccon 2005 [16]	Unclear risk	low risk	low risk	low risk	low risk	low risk	low risk
Lekas 2006 [7]	low risk	Unclear risk	high risk	high risk	low risk	low risk	low risk
Hahn 2007 [20]	Unclear risk	low risk	low risk	low risk	low risk	low risk	low risk
Memis 2008 [11]	Unclear risk	Unclear risk	high risk	high risk	low risk	low risk	low risk
Berardinis 2008 [9]	Unclear risk	low risk	low risk	low risk	low risk	low risk	low risk
Tuncel 2009 [21]	Unclear risk	Unclear risk	high risk	high risk	high risk	low risk	low risk
Kravchick 2009 [17]	high risk	low risk	high risk	high risk	high risk	low risk	low risk
He 2012	Unclear risk	Unclear risk	high risk	high risk	high risk	low risk	low risk
Pastore 2013	low risk	Unclear risk	low risk	Unclear risk	low risk	low risk	low risk
Liu 2013 [14]	Unclear risk	Unclear risk	high risk	high risk	low risk	low risk	low risk

5ARI 5α-reductase inhibitors, Fin finasteride, Dut dutasteride, MVD microvessel density, VEGF vascular endothelial growth factor, RR relative risk, MD mean difference, CI confidence interval

^afavors control